E Fund Management Co. Ltd. Grows Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

E Fund Management Co. Ltd. grew its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA) by 45.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,469 shares of the biotechnology company’s stock after purchasing an additional 11,351 shares during the quarter. E Fund Management Co. Ltd.’s holdings in ADMA Biologics were worth $625,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Hollencrest Capital Management purchased a new position in ADMA Biologics in the 3rd quarter worth approximately $30,000. Larson Financial Group LLC purchased a new position in ADMA Biologics in the 3rd quarter worth approximately $31,000. GAMMA Investing LLC lifted its stake in ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 967 shares in the last quarter. National Bank of Canada FI purchased a new position in ADMA Biologics in the 3rd quarter worth approximately $35,000. Finally, Vision Financial Markets LLC purchased a new position in ADMA Biologics in the 4th quarter worth approximately $51,000. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Stock Up 0.7 %

Shares of NASDAQ ADMA opened at $17.02 on Friday. ADMA Biologics, Inc. has a 1 year low of $5.88 and a 1 year high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The company has a 50 day simple moving average of $16.66 and a 200-day simple moving average of $17.96. The company has a market capitalization of $4.02 billion, a P/E ratio of 60.79 and a beta of 0.75.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. HC Wainwright raised their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Raymond James raised their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $25.00 price target on shares of ADMA Biologics in a report on Tuesday.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.